TY - JOUR AB -

Background

Intravenous immunoglobulin (IVIG), a pooled blood product acquired from multiple healthy donors, is an effective treatment for various types of autoimmune diseases, haematological disorders, and infectious diseases. Adverse haematological events such as throm-bocytopenia are rarely caused by IVIG.

Objectives

To investigate the phenomenon of IVIG-induced thrombocytopenia.

Materials & Methods

A case study and a review of the previous literature based on a search using MEDLINE (PubMed) and ICHUSHI (for Japanese literature) electronic databases.

Results

The present case of dermatomyositis exhibited two episodes of IVIG-induced thrombocytopenia, which occurred a few days after initiating IVIG and was significant within two weeks without haemorrhagic symptoms. Spontaneous remission of thrombocytopenia was repeatedly observed. Based on a review of five cases, the underlying disorders were autoimmune bullous diseases in three of the five cases. Polyethylene glycol-treated human immunoglobulin products were used in three of the five cases. The clinical course of IVIG-induced thrombocytopenia was similar to that in our present case.

Conclusion

Because of the rarity of severe haemorrhagic symptoms and spontaneous remission of IVIG-induced thrombocytopenia, discontinuation of IVIG due to thrombocytopenia is not straightforward.

AU - Maki Fukuzono AU - Naoko Okiyama AU - Riko Iwasaki AU - Ruriko Endo AU - Katsuhito Sasaki AU - Sae Inoue AU - Toshifumi Nomura DO - 10.1684/ejd.2022.4271 EP - 376 IS - 3 JO - European Journal of Dermatology PY - 2022/05/01 SN - 1167-1122 SP - 373 TI - Intravenous immunoglobulin-induced thrombocytopenia: a case report and review of the literature VL - 32 ER -